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Abstract
Background: Human airway surface liquid (ASL) has abundant antimicrobial peptides whose
potency increases as the salt concentration decreases. Xylitol is a 5-carbon sugar that has the ability
to lower ASL salt concentration, potentially enhancing innate immunity. Xylitol was detected for 8
hours in the ASL after application in airway epithelium in vitro. We tested the airway retention time
of aerosolized iso-osmotic xylitol in healthy volunteers.
Methods:  After a screening spirometry, volunteers received 10 ml of nebulized 5% xylitol.
Bronchoscopy was done at 20 minutes (n = 6), 90 minutes (n = 6), and 3 hours (n = 5) after
nebulization and ASL was collected using microsampling probes, followed by bronchoalveolar
lavage (BAL). Xylitol concentration was measured by nuclear magnetic resonance spectroscopy
and corrected for dilution using urea concentration.
Results: All subjects tolerated nebulization and bronchoscopy well. Mean ASL volume recovered
from the probes was 49 ± 23 µl. The mean ASL xylitol concentration at 20, 90, and 180 minutes
was 1.6 ± 1.9 µg/µl, 0.6 ± 0.6 µg/µl, and 0.1 ± 0.1 µg/µl, respectively. Corresponding BAL
concentration corrected for dilution was consistently lower at all time points. The terminal half-life
of aerosolized xylitol obtained by the probes was 45 minutes with a mean residence time of 65
minutes in ASL. Corresponding BAL values were 36 and 50 minutes, respectively.
Conclusion: After a single dose nebulization, xylitol was detected in ASL for 3 hours, which was
shorter than our in vitro measurement. The microsampling probe performed superior to BAL when
sampling bronchial ASL.
Introduction
Human airway surface liquid (ASL) contains many anti-
microbial substances, including lysozyme, lactoferrin,
and β defensins that are salt-sensitive. An increase in salt
concentration inhibits the antibacterial activity of these
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substances. Conversely, they are more potent at lower salt
concentrations [1-4].
Xylitol is a five-carbon sugar that is used as a nutritive
sweetener. When added to the apical surface of airway epi-
thelia, it can lower the ASL salt concentration, resulting in
enhanced antimicrobial properties. Using a radiotracer
method, we found that xylitol has low permeability across
an in vitro model of well-differentiated human airway epi-
thelia. Following addition to the apical surface, the
amount of xylitol in the ASL decreased progressively; after
8–12 hours, only 50% of the applied sugar had diffused
to the basolateral surface [5]. We recently tested the safety
of aerosolized xylitol in normal volunteers. All subjects
tolerated the exposures well without any significant
change in Forced Expiratory Volume (FEV) 1, or labora-
tory parameters [6].
The main aim of this study is to assess the rate at which
xylitol disappears from the ASL. It is difficult to measure
the actual salt concentration in the ASL because collecting
the fluid induces instantaneous changes in its composi-
tion [7]. Currently, the most widely used method for sam-
pling ASL is bronchoalveolar lavage (BAL); however, BAL
has limitations. First, it requires instillation of normal
saline into lung segments, resulting in enormous dilution
of the ASL. Second, there is a highly variable return of the
instilled liquid. Third, the relative contribution of airway
surface is insignificant compared to the alveolar surface
sampled by BAL. This results in underrepresentation of
the airway component when sampling ASL. Recently, a
new method for sampling human airway surface liquid
using a bronchoscopic microsampling (BMS) probe was
reported by Ishizaka et al [8]. This method has been used
to determine the ASL concentration of Levaquin after oral
administration [9]. We describe the results of xylitol con-
centration in ASL obtained using a microsampling probe
after aerosolization and compare it with the traditional
BAL sampling.
Methods
Xylitol permeability in human airway epithelia in vitro
For an osmolyte to lower ASL salt concentrations, it must
remain in ASL for some period of time before being
absorbed or cleared by the airway epithelium. We tested
the permeability of xylitol across well-differentiated air-
way epithelia using proton nuclear magnetic resonance
(NMR) spectroscopy and compared it with the results
from our previous experiment using 14C-labeled xylitol
tracer [5]. Xylitol (8 µmol in 60 µl) was added to the api-
cal surface of well-differentiated airway epithelia at time
zero. Apical liquid was then removed at 2, 4, 6, and 8
hours, and the xylitol concentration quantitated by NMR
spectroscopy.
Healthy volunteer study
The study was approved by the University of Iowa Institu-
tional Review Board and the Food and Drug Administra-
tion. After obtaining written informed consent, 18
subjects between the ages of 18 and 45 were consented.
In vitro half-life of xylitol in human airway epithelia Figure 1
In vitro half-life of xylitol in human airway epithelia. 
Panel A. Transmission electron micrograph of perfluorocar-
bon/OsO4 fixed human airway epithelia grown on a semi-
permeable membrane filter. The vertical bar in the left upper 
quadrant shows ASL height which measured 5 µm. Panel B. 
Xylitol concentration in the basolateral surface quantitated 
by NMR after addition to the apical surface.Respiratory Research 2006, 7:27 http://respiratory-research.com/content/7/1/27
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Exclusion criteria were FEV1 < 85% predicted, pregnancy,
any chronic medical condition, or known allergy to lido-
caine. Subjects received 10 ml of 5% xylitol (Danisco Cul-
tor, Kansas). Aerosolization was generated using a Pari LC
Plus nebulizer with Proneb Ultra compressor system (Pari
Inc, Monterey, CA). Xylitol was prepared by mixing crystal
sugar in sterile water (Abbott laboratories, IL) as previ-
ously described [6]. The first group of subjects (n = 6)
underwent bronchoscopy 20 minutes after nebulization,
the second group (n = 6) at 90 minutes, and the final
group (n = 5) at 180 minutes. One subject recruited for
the 180-minute group was excluded because of screening
FEV1 < 85% predicted and wasn't replaced. Blood was
drawn at baseline to obtain serum urea measurements.
Bronchoscopy
All bronchoscopies were performed by the same staff phy-
sicians in a standard fashion using a flexible fiberoptic
bronchoscope (model BF-30; Olympus). Subjects were
given local anesthesia using 4% lidocaine sprayed in the
oropharynx and 1% lidocaine directly instilled over the
vocal cords, carina, and both the main stem bronchi.
Under monitored sedation using intravenous midazolam
and fentanyl, bronchoscope was introduced into the right
lower lobe bronchus. After the channel was flushed with
air, a microsampling probe (model BC-401C; Olympus
Optical CO., LTD, Tokyo) was inserted into a segmental
bronchus as previously described [9]. The microsampling
probe has an outer sheath (1.8 mm diameter) and an
inner probe (1.1 mm diameter and 3 cm length) attached
to a stainless steel guide wire. The inner probe was
advanced into a distal airway, positioned against the
bronchial wall for 10 seconds to collect ASL, and then
withdrawn into the outer sheath. The probe with the
sheath was removed and the 3-cm tip of the inner probe
was cut into a pre-weighed tube. This procedure was done
three times and the sectioned inner probes were weighed.
BAL was then performed by instilling two 20-ml aliquots
of sterile normal saline into the lingula and right middle
lobe as previously described [10].
Specimen processing
BAL fluid was processed as previously described [6].
Briefly, the fluid was filtered through two layers of sterile
gauze and centrifuged for 10 minutes at 1500 rpm. The
cell-free fluid was frozen at -70°C until required for
assays. Microsampling probes were added to 2 ml of
saline in a pre-weighed tube, vortexed for 1 minute, and
the solution was stored at -20°C. The probes were then
dried and weighed again to measure the volume of ASL
recovered.
Nuclear magnetic resonance
NMR spectrometry is a form of absorption spectrometry
where the absorption of radio waves by the nuclei of a
molecule is a function of the structure of the molecule
[11]. The equipment used is a proton spectrometer, which
detects proton signals depending on the relative orienta-
tion of the hydrogen ions to the carbon moiety [500 mHz
NMR system (Varian Inova 500, Varian Inc., Palo Alto,
CA)]. NMR identifies xylitol and determines its concentra-
tion using area under the signal peak which indicates the
number of protons of that type and hence concentration
of the molecule. The NMR assay is very specific for xylitol
given its unique structure (C5H12O5) and its range of
detection is 5 µM – 6 M (0.0008 – 912 µg/µl). To assess
for interference with lidocaine, we obtained an NMR spec-
trum of lidocaine and found that the signal peaks for lido-
caine and xylitol did not overlap. (data not shown).
Xylitol concentration
Xylitol concentration in the ASL was calculated using the
previously described formula: ASL xylitol concentration =
BMS xylitol concentration × (2 + ASL volume)/(ASL vol-
ume) [9]. ASL volume recovered by the probes was esti-
mated by subtracting the wet and dry weight of the
probes. Xylitol concentration in the BAL was adjusted for
dilution using this formula: Alveolar concentration =
(Concentration in BAL × serum urea)/BAL urea (Infinity
urea assay kit, Thermo Electron, Melbourne, Australia).
Urea nitrogen concentration in the BAL is usually identi-
cal to corresponding serum concentration, as urea readily
crosses the alveolar-capillary membrane barrier [12].
Pharmacokinetic and statistical analysis
Xylitol concentrations for both methods were more than
two standard deviations higher for three subjects relative
to the remaining subjects. Accordingly, these measure-
ments were considered outliers and were therefore omit-
ted from the analysis. These three subjects had similar
baseline characteristics as the other subjects. Xylitol con-
centration in ASL obtained by the BAL and BMS methods
were analyzed using the one-compartment model with
first-order elimination and discontinuous zero-order
input.
In Equation 1, c(t) is the xylitol concentration at time = t,
R is the zero-order input rate constant, V is the volume of
distribution, k is the elimination rate constant and T is the
nebulization time. The term (t-T)+ is defined by:
Pharmacokinetic data from the remaining subjects were
simultaneously fitted to obtain population values for k
and R/V (volume-normalized input rate constant) param-
ct
R
Vk
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eters for different nebulization times using the interactive
WINFUNFIT. WINFUNFIT is a Windows-based applica-
tion, evolved from the general nonlinear regression pro-
gram FUNFIT [13].
The mean residence time (MRT), that provides an esti-
mate for the average time spent by xylitol molecules in the
ASL, was calculated as the reciprocal of k. Mean time
parameters may be generally defined as the average time
for a kinetic event to occur [14,15], and the residence time
of drug in a certain space qualifies as a kinetic event.
Results
Half-life of xylitol in airway epithelia
Following addition to the apical surface, the amount of
xylitol in the ASL progressively decreased; after 8 hours,
only 50% of the applied sugar had diffused to the basola-
teral surface (Figure 1). This low permeability suggests
that xylitol could effectively hold liquid on the apical sur-
face and lower the salt concentration. These results
obtained using NMR measurements were very similar to
those obtained using the radiotracer method, which was
previously published [5].
Human study
All subjects tolerated the xylitol nebulization and bron-
choscopy well. Mean age of the subjects was 26 years
(range 19–43), with a mean body mass index of 26.4
(standard deviation 2.8). All the subjects were nonsmok-
ers. Current medications used by the subjects included
contraceptive pills (n = 2), alprazolam and escitalopram
(n = 1), and minocycline (n = 1). The average nebuliza-
tion time of 10 mL xylitol using Pari-LC nebulizer was 48
± 11 minutes.
The mean ASL volume obtained using the microsampling
probe was 56 ± 6 µl, and was higher at 180 minutes as
compared to 20 minutes (77 ± 7 vs. 49 ± 9, p = 0.03, Fig-
ure 2). If ASL remains isotonic, these data suggest that xyl-
itol both lowers the salt concentration and increases the
ASL volume. Using urea dilution method, we estimated
the volume of epithelial lining liquid sampled by BAL to
be 16 ± 9 µl, 16 ± 11 µl, and 14 ± 7 µl at 20, 90, and 180
minutes, respectively. These volumes are lower than those
measured by the BMS probe method. However, whereas
the BMS probe method only samples bronchial surface
liquid, BAL samples both bronchial and alveolar liquid.
Xylitol concentration at various time points in the BMS
probe and BAL is shown in Figure 3. Linear shape of the
time-concentration graph using a semi-logarithmic model
predicts a first-order kinetics. The concentration of xylitol
in bronchial ASL collected by the BMS probe was at least
one log higher than the BAL concentration after correcting
for dilution.
Figure 4 shows the plots for simulated xylitol concentra-
tion-time profile for BAL and BMS methods. The popula-
tion estimates for the k, t1/2, R/V, and MRT values for the
BAL and BMS methods are presented in Table 1. The half-
life was 34.5 minutes for the BAL and 45.0 minutes for the
Semi-logarithmic plot of concentration of xylitol in human  ASL plotted against time from the start of nebulization Figure 3
Semi-logarithmic plot of concentration of xylitol in human 
ASL plotted against time from the start of nebulization. The 
closed circles represent BMS probe data and open circles 
represent BAL data.
ASL volume recovered by BMS probe over time Figure 2
ASL volume recovered by BMS probe over time. * p = 0.03.Respiratory Research 2006, 7:27 http://respiratory-research.com/content/7/1/27
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BMS method. The MRT for the BMS method was 64.9
minutes, which is comparable to 49.8 minutes obtained
for the BAL method.
Discussion
In this study, we evaluated the airway retention time of
aerosolized xylitol using two methods. We previously
reported the safety of aerosolized xylitol in normal volun-
teers. We now show that xylitol can be deposited in con-
ducting airways after nebulization. After a single dose
nebulization, xylitol was detected in ASL for at least 3
hours. This retention time is shorter than our in vitro data
using the same detection method; however, the prolonged
nebulization time (mean of 48 minutes) and the constant
airway exposure during that time have to be considered
when interpreting these data. Further, we found that the
concentration was higher in the airways as sampled by the
probe compared to alveoli plus airways as sampled by
BAL.
ASL collection using a microsampling probe may prove
valuable as a research tool and possibly aid in patient care.
We found it safe and easy to use. BAL mostly samples alve-
olar fluid and, hence, significantly underrepresents con-
centration of products in the airway. The probe, in
contrast, collects fluid directly from the airways without
much dilution by alveolar liquid. A limitation of the
probe is that it most likely collects volume of liquid in
excess of the actual ASL by capillary action, drawing liquid
from the mucosa and submucosa [16]. It may also stimu-
late submucosal gland secretion. Currently, however,
there is no accurate method of ASL collection without
altering its composition.
Not surprisingly, xylitol concentration was higher using
BMS probe sampling compared to BAL, which is expected
given the inhaled route of administration and specific
sampling of ASL without any dilution by alveolar com-
partment. This is in contrast to the previous study using a
microsampling probe and BAL, where Levaquin concen-
trations obtained from BAL were twice as high as that
from the airway probe after oral dosing [9].
As to mechansims of clearance of xylitol from the airways,
there are several possibilities, including mucociliary clear-
ance, exhalation during tidal breathing, diffusion across
the airway epithelia, and drug metabolism. Our data does
not favor a particular mechanism. The airway retention
time was significantly longer in vitro than in vivo. In our in
vitro  experiments, there are only airway epithelial cells
without mucociliary clearance and relatively large vol-
umes of xylitol were added to the apical surface of respira-
tory epithelim, which may have prolonged the retention
time by adding to the distance of diffusion.
It was interesting to note that the ASL volume retrieved by
the probes was higher after 3 hours compared to earlier
time points. One possible explanation is the learning
curve with the use of the microsampling probe to collect
ASL. In this study, however, we recruited and completed
the study on subjects assigned to the 3-hour time point
before the 1.5-hour group. One of the possibilities for the
increase in ASL volume at 3 hours is an osmotic effect of
xylitol, resulting in dilution of ASL.
In the past, xylitol was used as an intravenous nutrition in
doses as high as 0.25 gm/kg/hr [17]. After intravenous
use, the half-life of xylitol is about 20 minutes in humans
[18]. Exogenous xylitol is rapidly oxidized in the liver by
NAD-linked polyol dehydrogenase into xylulose, which is
then is phosphorylated and eventually metabolized by
glycolysis or gluconeogenesis [19]. Therefore, to be effec-
tive in the lower respiratory tract, xylitol must be admin-
istered via aerosol route.
Table 1: Summary of the population pharmacokinetic 
parameters of xylitol in ASL obtained by the BMS probe and BAL 
liquid.
BMS Probe BAL
k (1/min) 0.015 0.02
t1/2 (min) 45.0 34.5
R/V (µg/µl-min) 0.032 0.0014
MRT (min) 64.9 49.8
Simulated xylitol concentration versus time profile for the  BMS probe and BAL methods Figure 4
Simulated xylitol concentration versus time profile for the 
BMS probe and BAL methods. The solid line represents the 
simulated curve using population parameters (Table 1) 
obtained for the BMS probe method and the dashed line rep-
resents the simulated curve for the BAL method.Publish with BioMed Central    and   every 
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To our knowledge, this is the first study to assess airway
deposition and retention time of aerosolized xylitol. A few
limitations must be acknowledged. First, this study was
done in healthy volunteers. In patients with lung disease,
such as cystic fibrosis and those who are critically ill, the
airway retention time may be different due to difference in
epithelial integrity and permeability. Second, we did not
study time points beyond 3 hours after nebulization.
Third, because of the prolonged nebulization time and
the preparation time for bronchoscopy, we were unable to
assess the early pharmacokinetics of aerosolized xylitol.
Fourth, we did not study clearance in proximal airway seg-
ments such as trachea or main stem bronchi. Finally, for
safety and comfort reasons, ASL samples were collected
from different sets of volunteers at different time points,
which may have contributed to intersubject variability of
the clearance estimates.
In conclusion, the MRT of aerosolized xylitol was greater
than 1 hour. Aerosolized xylitol may be effective by tran-
siently enhancing the innate immunity of the ASL and
maintaining a sterile lung compartment, and, thus, pre-
vent colonization in patients who are ventilated and in
subjects with cystic fibrosis.
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